BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Patients With Non Muscle Invasive Bladder Cancer.

Trial Profile

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Patients With Non Muscle Invasive Bladder Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2015

At a glance

  • Drugs BCG vaccine (Primary) ; Zastumotide (Primary) ; AS15
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Feb 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 17 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 30 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top